Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totalling 3,170,000 shares, an increase of 10.5% from the July 15th total of 2,870,000 shares. Based on an average daily volume of 343,600 shares, the days-to-cover ratio is presently 9.2 days.
Insider Buying and Selling at Keros Therapeutics
In other news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the sale, the director now owns 119,522 shares in the company, valued at approximately $5,260,163.22. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 22.90% of the company’s stock.
Institutional Trading of Keros Therapeutics
Large investors have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Keros Therapeutics during the second quarter worth $128,000. Ameritas Investment Partners Inc. boosted its stake in shares of Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after purchasing an additional 324 shares in the last quarter. Quest Partners LLC increased its position in Keros Therapeutics by 23,945.0% during the 2nd quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock worth $220,000 after purchasing an additional 4,789 shares in the last quarter. XTX Topco Ltd bought a new position in Keros Therapeutics in the 2nd quarter valued at approximately $228,000. Finally, Arizona State Retirement System acquired a new stake in Keros Therapeutics in the fourth quarter valued at approximately $231,000. Institutional investors and hedge funds own 71.56% of the company’s stock.
Analyst Ratings Changes
View Our Latest Stock Report on KROS
Keros Therapeutics Stock Performance
Shares of KROS stock traded down $0.50 during trading on Friday, hitting $45.54. The company had a trading volume of 265,099 shares, compared to its average volume of 379,065. The firm has a market capitalization of $1.64 billion, a P/E ratio of -8.84 and a beta of 1.23. Keros Therapeutics has a one year low of $27.02 and a one year high of $73.00. The stock’s 50-day moving average price is $46.84 and its 200 day moving average price is $54.69.
Keros Therapeutics (NASDAQ:KROS – Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The firm had revenue of $0.04 million during the quarter. During the same quarter last year, the company posted ($1.27) EPS. On average, research analysts anticipate that Keros Therapeutics will post -4.8 earnings per share for the current fiscal year.
Keros Therapeutics Company Profile
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Further Reading
- Five stocks we like better than Keros Therapeutics
- 10 Best Airline Stocks to Buy
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Which Wall Street Analysts are the Most Accurate?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.